Angelini Pharma’s acquisition of Catalyst Pharmaceuticals is part of a transformation strategy focused on neurological medicines. Catalyst’s top product is Firdapse, the first FDA-approved drug for a particular rare neuromuscular disorder.
The post Angelini Pharma’s $4B Acquisition Adds Rare Disease Drugs to a Global Growth Strategy appeared first on MedCity News.
